TIMOTHY STOVER - 30 Aug 2023 Form 3 Insider Report for NexImmune, Inc. (NEXI)

Role
VP, Corporate Controller
Signature
/s/ Nadia Do Canto, Attorney-in-fact
Issuer symbol
NEXI
Transactions as of
30 Aug 2023
Net transactions value
$0
Form type
3
Filing time
08 Sep 2023, 20:23:59 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NEXI Common Stock 71,000 30 Aug 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NEXI Stock Option (right to buy) 30 Aug 2023 Common Stock 13,475 $0.4100 Direct F2
holding NEXI Stock Option (right to buy) 30 Aug 2023 Common Stock 15,925 $1.03 Direct F2
holding NEXI Stock Option (right to buy) 30 Aug 2023 Common Stock 6,375 $1.03 Direct F3
holding NEXI Stock Option (right to buy) 30 Aug 2023 Common Stock 32,000 $0.4100 Direct F4
holding NEXI Stock Option (right to buy) 30 Aug 2023 Common Stock 11,625 $0.4100 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest 100% on the 18-month anniversary of November 22, 2022, subject to Mr. Stover's continued service through the applicable vesting date.
F2 25% of this option vested and became exercisable on July 6, 2022, with the remainder vesting in 36 equal monthly installments thereafter.
F3 25% of this option vested and became exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter.
F4 25% of this option will vest and become exercisable on April 4, 2024, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Exhibit 24.1